Panobinostat (LBH-589)

LBH589, a novel hydroxamate analog HDAC inhibitor, has been shown to induce acetylation of histone H3 and H4, increase p21 levels, disrupt the chaperone function of hsp90, and induce cell-cycle G1 phase accumulation and apoptosis of K562 cells and acute leukemia MV4-11 cells. The anti-tumor effect by Panobinostat was also demonstrated in multiple myeloma, NSCLC as well as castrate-resistant prostate cancer cell lines.

Synonyms: LBH-589; LBN-589; LBH589; NVP-LBH589
Technical Data: Molecular Weight - 349.44; Molecular formula - C21H23N3O2; CAS No - 404950-80-7

Ordering Information: Product Number - EC-000.2287; Price and Availability: Inquire This product is also available to buy in bulk quantities.

Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.

References:
1. Tan J, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010 Feb 4;3:5.
2. Chen S, et al. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11032-7.
3. Minucci S, et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006 Jan;6(1):38-51.